Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06333249 · ClinicalTrials.gov registry record · Phase 2
A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)
A Phase 2 study of X-Linked Retinitis Pigmentosa, sponsored by Beacon Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 6
- Study locations
NCT06333249: Active Phase 2 study of X-Linked Retinitis Pigmentosa, sponsored by Beacon Therapeutics.
NCT06333249 is a Phase 2 study of X-Linked Retinitis Pigmentosa that is active but no longer recruiting, run by Beacon Therapeutics. The registered enrollment target is 14 participants, below the 57-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (75% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06333249, a Phase 2 study of X-Linked Retinitis Pigmentosa, is active but no longer recruiting, sponsored by Beacon Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
Conditions Studied
Interventions
- BIOLOGICAL rAAV2tYF-GRK1-RPGR
Study Locations (6)
Ohio
- Cincinnati Eye Institute - Cincinnati
- Cleveland Clinic - Cleveland
Florida
- University of Florida - Jacksonville
Massachusetts
- Boston Children's Hosptial - Boston
Oregon
- Casey Eye Institute - Portland
Texas
- Retina Foundation of the Southwest - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-04-13 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT06333249 still lists
NCT06333249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 57-participant average among 8 other X-Linked Retinitis Pigmentosa trials with a reported enrollment target (75% lower).
The record links to 1 condition, with X-Linked Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which rAAV2tYF-GRK1-RPGR is the first listed.
NCT06333249 lists 6 locations in 5 states (Ohio, Florida, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT06333249 about?
NCT06333249 is a clinical study titled "A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)". This study will evaluate the safety and efficacy of a recombinant adeno-associated virus vector (rAAV2tYF-GRK1-RPGR) in patients with X-linked retinitis pigmentosa caused by RPGR mutations.
What is the current status of trial NCT06333249?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-04-13. Estimated completion is 2027-02.
What conditions does trial NCT06333249 study?
This clinical trial studies the following conditions: X-Linked Retinitis Pigmentosa.
What interventions are being tested in trial NCT06333249?
The interventions under investigation include: rAAV2tYF-GRK1-RPGR (BIOLOGICAL).
Who is sponsoring clinical trial NCT06333249?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06333249 being conducted?
This trial has 6 study locations across Florida, Massachusetts, Ohio, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-Linked Retinitis Pigmentosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06333249's enrollment target sits among peer trials
14 9th of 8 the lowest of 8 other X-Linked Retinitis Pigmentosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other X-Linked Retinitis Pigmentosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
ACTIVE NOT RECRUITING · Phase 2
-
4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations
ACTIVE NOT RECRUITING · Phase 1
-
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Follow-up Gene Therapy Study for RPGR- XLRP
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy